A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Non-small Cell Lung Cancer|Squamous Cell Carcinoma of the Head and Neck|Breast Cancer|Colorectal Cancer|Melanoma|Bladder Cancer|Ovarian Cancer|Endometrial Cancer|Merkel Cell Carcinoma|GastroEsophageal Cancer|Renal Cell Carcinoma|Castration-resistant Prostate Cancer
Interventions: DRUG: Etrumadenant|DRUG: Zimberelimab
Sponsor: Arcus Biosciences, Inc.